Section Arrow
FATE.NASDAQ
- Fate Therapeutics
Quotes are at least 15-min delayed:2025/06/03 09:47 EDT
Last
 1.34
+0.04 (+3.08%)
Day High 
1.35 
Prev. Close
1.3 
1-M High
1.39 
Volume 
144.09K 
Bid
1.34
Ask
1.35
Day Low
1.24 
Open
1.3 
1-M Low
0.9101 
Market Cap 
149.02M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.23 
20-SMA 1.13 
50-SMA 1.07 
52-W High 5.92 
52-W Low 0.66105 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.49/-1.20
Enterprise Value
226.87M
Balance Sheet
Book Value Per Share
2.52
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
13.63M
Operating Revenue Per Share
1.04
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TRAWTraws Pharma Inc2.26+0.84+59.15%-- 
REVBRevelation Biosciences Inc0.9516+0.1286+15.63%-- 
RENBRenovaro0.3818+0.0919+31.70%-- 
NCNANuCana plc0.0408+0.0028+7.37%-- 
AGENAgenus4.3816+0.2516+6.09%0.14PE
Quotes are at least 15-min delayed:2025/06/03 09:47 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.